Lead success for Neurogen
Branford, CT, US-based Neurogen has announced the successful passage of its lead compound NGD 97-1 into Phase II efficacy studies. The result of a collaboration with Pfizer, the compound has been developed for the treatment of Alzheimer's disease.
Pfizer is conducting the Phase II study in the US. The drug operates through precise modulation of the GABA neurotransmitter system. Neurogen's research has led to a number of compounds that act more specifically on the GABA system than existing drugs.